A novel 1726-nm laser (AviClear) developed by Cutera for patients with mild to severe inflammatory acne vulgaris has received FDA clearance, according to a press release published by the company. The clearance comes after a 12-month clinical study, where researchers found that 92% of patients who were treated with the 1726-nm laser saw noticeable improvements in acne clearance and their skin quality. The treatment is the first of its kind to become available for clinical use after receiving initial clearance from the FDA in March 2022. In addition, the FDA has also recognized that the new treatment may offer long-term results after only three 30-minute sessions by targeting and suppressing the sebaceous glands. The novel 1726-nm laser is a prescription-free option for patients and their physicians. For more information, individuals and practitioners can visit aviclear.com.
June 22, 2023